The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C Infection. by Moore, Penelope L. et al.
JOURNAL OF VIROLOGY, Feb. 2008, p. 1860–1869 Vol. 82, No. 4
0022-538X/08/$08.000 doi:10.1128/JVI.02187-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
The C3-V4 Region Is a Major Target of Autologous Neutralizing
Antibodies in Human Immunodeficiency Virus Type 1
Subtype C Infection
Penny L. Moore,1† Elin S. Gray,1† Isaac A. Choge,1 Nthabeleng Ranchobe,1 Koleka Mlisana,2
Salim S. Abdool Karim,2 Carolyn Williamson,3 Lynn Morris,1*
and the CAPRISA 002 Study Team
AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa1; Centre for the
AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa2; and
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa3
Received 5 October 2007/Accepted 19 November 2007
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1)
subtype C infections is often characterized by high titers, but the response is type specific with little to no
cross-neutralizing activity. The specificities of these early neutralizing antibodies are not known; however, the
type specificity suggests that they may target the variable regions of the envelope. Here, we show that
cross-reactive anti-V3 antibodies developed within 3 to 12 weeks in six individuals but did not mediate
autologous neutralization. Using a series of chimeric viruses, we found that antibodies directed at the V1V2,
V4, and V5 regions contributed to autologous neutralization in some individuals, with V1V2 playing a more
substantial role. However, these antibodies did not account for the total neutralizing capacity of these sera
against the early autologous virus. Antibodies directed against the C3-V4 region were involved in autologous
neutralization in all four sera studied. In two sera, transfer of the C3-V4 region rendered the chimera as
sensitive to antibody neutralization as the parental virus. Although the C3 region, which contains the highly
variable 2-helix was not a direct target in most cases, it contributed to the formation of neutralization
epitopes as substitution of this region resulted in neutralization resistance. These data suggest that the C3 and
V4 regions combine to form important structural motifs and that epitopes in this region are major targets of
the early autologous neutralizing response in HIV-1 subtype C infection.
The envelope glycoprotein (Env) of human immunodefi-
ciency virus type 1 (HIV-1) is the target of neutralizing anti-
bodies (NAbs). Almost all individuals develop NAbs to their
own virus (autologous neutralization) within a few months of
infection (12, 21, 32, 37). In subtype C, these antibodies de-
velop to high titer and are type specific with little or no cross-
neutralizing activity within the first year of infection (12, 21).
The target(s) of these early antibodies are unknown, but their
type specificity suggests that they might recognize the most
variable regions of Env, namely V1V2, V3, V4, and V5. Char-
acterization of the targets of NAbs in early infection will allow
a better understanding of the epitopes involved in early neu-
tralization.
Anti-V3 antibodies play a minimal role in neutralization of
primary viruses (1, 22) because the V3 loop is occluded on the
trimeric Env (13, 19, 30). Comparisons of the V3 regions of
subtype B and subtype C viruses suggest that there are subtype-
specific selection pressures applied to this region. Among sub-
type B viruses, a high nonsynonymous-to-synonymous substi-
tution ratio typifies the V3 region, whereas in subtype C this
region remains relatively conserved, with a much higher non-
synonymous-to-synonymous substitution ratio in the C3 region
downstream of V3 (8, 17). The highly conserved nature of V3
in subtype C suggests that it is unlikely to play a role in type-
specific neutralization. However, anti-V3 antibodies have been
implicated in autologous neutralization of South African sub-
type C viruses (2).
The V1V2 region regulates neutralization sensitivity by oc-
cluding conserved epitopes such as the coreceptor binding site
(3, 18–20, 30, 35, 39). Variable regions (V1 to V4) have also
been implicated in shielding neutralization determinants in
subtype C viruses, where infection may be mediated by viruses
with relatively short variable loops and correspondingly high
sensitivity to neutralization by donor sera (5). We have previ-
ously shown that the V1V2 length of subtype C viruses corre-
lated with resistance to broadly cross-neutralizing serum (12)
and that a corresponding relationship exists between the length
of the variable loops (V1V2 and V1 to V4) of subtype C viruses
and their ability to induce antibodies which cross-neutralize
heterologous subtype C viruses (31).
In contrast to the role of V1V2 in shielding conserved neu-
tralization epitopes, V1V2 may also act as a neutralization
target in laboratory-adapted isolates (6) and primary isolates
(10, 15, 24, 25, 29, 38). In subtype C viruses, the role of V1V2
in neutralization resistance was examined by generating chi-
meric viruses within four transmission pairs (33). In most cases
longer V1V2 loops conferred neutralization resistance while
viruses with shorter loops were generally more sensitive, in
accordance with the idea that V1V2 masks neutralization-sen-
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sitive sites. However, in some viruses, longer loops conferred
neutralization sensitivity, possibly because they contained neu-
tralization epitopes. We have also previously suggested that
V1V2 may be a potential target of autologous NAbs in subtype
C infection (12).
Unlike V1V2, the role of V4 and V5 in neutralization resis-
tance is not clear, although these regions are likely to impact
Env conformation and glycan packing (16, 36, 37), thereby
sterically limiting accessibility to neutralization determinants.
The V4 region in subtype C viruses is generally shorter and
significantly more positively charged than in subtype B viruses
(9, 21, 23). Increased length in the V4 region in subtype C
viruses correlated with resistance to neutralization in linked
donor plasma but less so for heterologous plasma, suggesting
that changes in V4 may be driven by type-specific NAbs (34).
As with the V3 region of HIV-1, there are distinct structural
differences between subtypes B and C in the 2-helix of C3,
located in the outer domain of gp120 slightly upstream of the
V3 loop. As mentioned, the C3 region of subtype C viruses
appears to be under strong diversifying pressure (8). Further-
more, the 2-helix of subtype C viruses is more solvated and
shows greater amphipathicity than its subtype B counterpart
(9), despite high sequence entropy at the polar faces. Although
it is not clear whether these structural and diversity differences
in subtype C reflect subtype-specific properties of NAbs,
unique mutations within the 2-helix were linked with resis-
tance to neutralization by donor plasma (34). However, viruses
chimeric for the 2-helix did not show altered susceptibility to
neutralization by donor plasma, implying that another re-
gion(s) of Env together with the 2-helix plays a role in resis-
tance to neutralization.
Here, we have attempted to dissect the specificities of anti-
bodies responsible for autologous neutralization in the first
year of infection with HIV-1 subtype C, focusing on gp120,
where the regions of greatest variability are located.
MATERIALS AND METHODS
Participants. Participants were from the CAPRISA (Centre for the AIDS
Programme of Research in South Africa) 002 Acute Infection study, a cohort of
245 high-risk HIV-negative women which was established in 2004 in Durban,
South Africa, for follow-up and subsequent identification of HIV seroconversion.
We previously reported that 14 of these individuals had potent but type-specific
autologous neutralizing activity (12). In this study, six of these individuals were
selected for in-depth analysis on the basis of potent autologous neutralizing
responses but absence of cross-neutralizing capacity at 12 months postinfection.
Written informed consent was obtained from all participants. This study received
ethical approval from the University of the Witwatersrand, University of
KwaZulu-Natal, and University of Cape Town.
Cell lines. The JC53-bl cell line, engineered by J. Kappes and X. Wu, was
obtained from the NIH AIDS Research and Reference Reagent Program. 293T
cells were obtained from George Shaw (University of Alabama, Birmingham,
AL). Both cell lines were cultured in Dulbecco’s modified Eagle’s medium
(Gibco BRL Life Technologies) containing 10% heat-inactivated fetal bovine
serum and 50 g/ml gentamicin (Sigma). Cell monolayers were disrupted at
confluence by treatment with 0.25% trypsin in 1 mM EDTA.
Peptide ELISAs. Peptides (33-mer) representing the V3 region of six subjects
were purchased from NMI peptides (Reutlingen, Germany). Autologous pep-
tides spanning the V1V2 region (15-mer peptides overlapping by 5 amino acids)
of the gp160 were purchased through New England Peptides (Gardner, MA).
Peptides from the Ebola surface proteins were used as irrelevant peptide con-
trols. Peptides were coated onto high-binding 96-well enzyme-linked immu-
nosorbent assay (ELISA) plates at a concentration of 2.5 g/ml in sodium
bicarbonate buffer (pH 8.5), 50 l/well, overnight at 4°C. Unbound peptide was
removed by washing four times with phosphate-buffered saline containing 0.3%
Tween 20 (wash solution), and plates were blocked for 1 h at room temperature
with 200 l of phosphate-buffered saline, 0.3% Tween 20, and 5% nonfat milk
(block solution). Serum samples were diluted 1:500 in block solution, and 100 l
per well was added, followed by incubation at room temperature for 1 h. Plates
were washed four times with wash solution before the addition of 100 l of
secondary antibody (alkaline phosphatase-labeled goat anti-human [Fc-specific]
antibody [Sigma-Aldrich, St. Louis, MO] diluted 1:1,000 in blocking solution) for
1 h at 37°C. After four washes with wash solution, bound antibody was detected
using p-nitrophenyl phosphate substrate and stopped by the addition of 25 l of
3 M NaOH stop solution. Samples were scored positive when the optical density
at 405 nm (OD405) exceeded 2.5 times the negative control.
Viruses. Envelope clones CAP45.2.00.G3J, CAP63.2.00.A9J, CAP84.2.00.32J,
CAP88.2.00.B5J, CAP206.2.00.08J, and CAP239.2.00.G3J have been previously
described (12). The gp120 sequences and the lengths and numbers of predicted
N-linked glycosylation sites of the V1V2, C3-V4, V4, and V5 regions are shown
in Fig. 3 and Table 1, respectively. Env-pseudotyped viruses were obtained by
cotransfecting the Env plasmid with pSG3Env (37) using Fugene transfection
reagent (Roche) as previously described (12).
Generation of chimeras. Chimeric gp160 proteins were created using an over-
lapping PCR strategy with the inserts and flanking regions amplified in separate
reactions (primer sequences are available on request from the authors). After
linkage, the 3-kb chimeric PCR fragments, generated using env A and env M
primers (7), were cloned into the pCDNA 3.1D-TOPO vector (Invitrogen) and
screened for function as previously described (11). Chimerism was confirmed by
sequence analysis.
gp160 sequencing and analysis. Cloned env genes were sequenced using an
ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied
Biosystems, Foster City, CA) and resolved on an ABI 3100 automated genetic
analyzer. The full-length gp160 sequences were assembled and edited using
Sequencher software, version 4.0 (Genecodes, Ann Arbor, MI). The number of
potential N-linked glycosylation sites (PNGS) was determined using N-glycosite
(http:/www.hiv.lanl.gov/content/hiv-db/GLYCOSITE/glycosite.html). Multiple se-
quence alignments were performed using Clustal X (version 1.83) and edited with
BioEdit (version 5.0.9). Entropy plots were generated using the software Entropy-
One (http://www.hiv.lanl.gov/content/hiv-db/ENTROPY/entropy.html).
Neutralization assays. Neutralization was measured as described previously
(12) by a reduction in luciferase gene expression after a single round infection of
JC53-bl cells with Env-pseudotyped viruses (26). Titers were calculated as the
inhibitor concentration (IC50) or reciprocal plasma/serum dilution (ID50) caus-
ing 50% reduction of relative light units. Peptide adsorption neutralization assays
TABLE 1. Characteristics of parental viruses
Participant
identifier Env clone name Accession no.
Length (aa) and no. of PNGS of the indicated regiona
V1V2 2-V4 V4 alone V5
Length PNGS Length PNGS Length PNGS Length PNGS
CAP45 CAP45.2.00.G3J EF203960 66 5 75 7 22 3 17 1
CAP84 CAP84.2.00.32J EF203963 66 5 77 6 24 4 16 1
CAP63 CAP63.2.00A9J EF203973 72 6 83 5 30 2 17 3
CAP88 CAP88.2.00.B5J EF203972 73 5 76 5 22 3 18 2
CAP206 CAP206.2.00.08J EF203967 70 6 78 6 25 4 18 1
CAP239 CAP239.2.00.G3J EF203983 64 5 84 9 31 6 20 2
a aa, amino acids.
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were performed by preincubating serum with autologous peptides at a final
concentration (after addition of cells) of 50 g/ml for 1 h at 37°C before con-
tinuing with the standard neutralization assay.
RESULTS
Anti-V3 antibodies are present early in subtype C infection
but do not mediate autologous neutralization. Autologous V3
peptides (33-mer) were synthesized and used to measure anti-
V3 binding antibodies in sera from six HIV-1-infected individ-
uals during the first year of infection. Sera were tested against
both autologous and heterologous V3 peptides. In all individ-
uals, anti-V3 binding antibodies developed early in infection,
with antibodies first detected between 3 and 12 weeks postin-
fection (p.i). (Fig. 1A). In one case, anti-V3 antibodies pref-
erentially recognized the autologous peptide (participant
CAP45) although there was still good recognition of heterol-
ogous peptides. In the remaining individuals, there was a high
level of cross-reactivity between peptides, with binding to the
autologous peptide no stronger than to heterologous peptides.
Although the extensive cross-reactivity of anti-V3 antibodies
makes it unlikely such antibodies mediate type-specific autol-
ogous neutralization, anti-V3 antibodies have been previously
implicated in autologous neutralization (2). We therefore per-
formed neutralization assays in which serum was preincubated
with peptides to adsorb anti-V3 antibodies. Binding ELISAs
where serum was preincubated with peptides confirmed that
adsorption of anti-V3 antibodies was efficient (data not
shown). However, in all six subjects, we observed no change in
autologous NAb titers in the presence of autologous peptides
(Fig. 1B), suggesting that these binding antibodies do not me-
diate autologous neutralization.
What are the likely targets of the autologous neutralizing
response? The type specificity of the autologous response sug-
gests that these antibodies may target the most variable regions
of the Env. Entropy analysis of gp160 sequences from six in-
dividuals at enrollment showed that the V1V2, V4, and V5
regions as well as the C3 region (specifically the 2-helix) were
the most variable between viruses (Fig. 2, gray regions). There
were numerous substitutions, deletions, insertions, and shifts
in glycosylation sites in these regions (Fig. 3). The V3 region
showed minimal diversity, as has been reported previously for
subtype C viruses (8, 17). The absence of variability in the V3
region supports our data, suggesting that this region is not the
target of the potent neutralizing responses in these individuals.
We therefore turned our attention to the remaining variable
loops of the HIV-1 envelope, namely, V1V2, V4, and V5.
Using a series of chimeric viruses, schematically shown in Fig.
2, we attempted to transfer sensitivity to NAbs by exchanging
variable loops between pairs of viruses that did not share
neutralization determinants.
Anti-V1V2 antibodies targeting conformational epitopes
mediate autologous neutralization in some individuals. (i)
Chimeras. We generated three pairs of viruses chimeric for the
V1V2 region using an overlapping PCR strategy. Pairs of chi-
meras were tested, along with both parental viruses, in neu-
tralization assays against autologous sera at various time points
up to 1 year p.i. (excepting participant CAP63, who progressed
rapidly to AIDS and entered a treatment program at 37 weeks
p.i.).
Results of autologous neutralization assays are shown in Fig.
4A (data not shown for CAP206 and CAP239 chimeras). Each
graph represents neutralization by serum from one individual
FIG. 1. (A) Development of anti-V3 binding antibodies in six individuals (absorbance at 405 nm [Abs405] versus weeks postinfection). Binding
of each serum to the autologous peptides is shown in black, with binding to heterologous peptides shown in gray. (B) Peptide adsorption
neutralization assays. Sera were preincubated with autologous V3 peptides (black) or irrelevant peptides (gray) prior to performing neutralization
assays against the autologous enrollment virus. Neutralization titer (ID50) is plotted against the number of weeks p.i.
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of two chimeras and their parental viruses. In four of six par-
ticipants (CAP45, CAP88, CAP206, and CAP239) a propor-
tion of autologous neutralization appeared to be mediated by
anti-V1V2 antibodies, as reflected by acquisition of partial or
complete sensitivity in chimeric viruses in which the V1V2 was
swapped in and by loss of some sensitivity in viruses where the
autologous V1V2 had been swapped out. For example, serum
from participant CAP45 neutralized the parental virus CAP45
(IC50 of 6,377 by 12 months p.i.) (Fig. 4A, solid red line) but
showed no activity against CAP84 (solid blue line) even after 1
year of infection. However, when the V1V2 region from
CAP45 was inserted into the CAP84 backbone (yielding the
chimera designated 84/45/84-V1V2) (Fig. 4A, dotted blue
line), this chimera acquired partial sensitivity to serum from
CAP45 (IC50 of 392). Conversely, the reverse chimera (45/84/
45-V1V2; dotted red line) was slightly less sensitive than the
parental CAP45 virus to neutralization by CAP45 serum. Col-
lectively, these data suggest that some of the NAbs in serum
from CAP45 are directed at the V1V2 region. Chimera 63/88/
63-V1V2 was especially striking, and acquired nearly complete
sensitivity to serum from CAP88, with titers similar to those
measured against the autologous parental viruses at 12 months
p.i. In two other sera, CAP206 (IC50 of 102 against 239/206/
239-V1V2 compared to autologous IC50 of 1,843) and CAP239
(IC50 of 1,252 against 206/239/206-V1V2 compared to autolo-
gous IC50 of 3,535), anti-V1V2 NAbs were also implicated in
autologous neutralization (data not shown). In two partici-
pants (CAP63 and CAP84), there was no evidence that neu-
tralization was mediated by anti-V1V2 antibodies as parental
and chimeric viruses were equally sensitive to neutralization.
(ii) Peptides. In order to determine whether the neutraliza-
tion epitopes in V1V2 were linear, we performed adsorption
neutralization assays using autologous V1V2 peptides for all
six individuals (15-mer peptides overlapping by 5-mer). How-
ever, none of these peptides was able to inhibit neutralization
of parental viruses by matched sera. Thus, while the use of
chimeric viruses suggested the presence of neutralization tar-
gets in V1V2 in four cases, these data suggested that these
epitopes are likely to be of a conformational nature. In con-
trast to V3 binding antibodies, only one of six individuals had
detectable binding antibodies to these V1V2 peptides (ELISA
data not shown). Binding antibodies to the peptide TNKSMN
GEIDMKEEM in the V1 region were detected at approxi-
mately 47 weeks p.i in CAP88 serum. Interestingly, this re-
FIG. 2. Entropy analysis of six amino acid Env (gp160) sequences. Regions of greatest variability (V1V2, C3, V4, and V5) are highlighted in
gray. Above the entropy plot is a schematic depicting pairs of chimeric viruses constructed for this study.
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sponse was considerably later than the autologous NAb
response in CAP88, which was detectable at 22 weeks p.i. (12),
although it was similar to the timing of anti-V1V2 NAbs de-
tected using the chimera 63/88/63-V1V2.
Antibodies targeting the V4 and V5 regions do not play a
major role in autologous neutralization. Viruses chimeric for
the V4 and V5 regions were created from six parental env
clones (however, chimeras between CAP206 and CAP239 for
the V4, V5, C3, and C3-V4 regions were nonfunctional) and
were tested in neutralization assays against parental sera from
multiple time points (Fig. 4A). NAbs targeting the V4 region
were detected only in CAP63, where insertion of the CAP63
V4 region into a CAP88 backbone (88/63/88-V4) showed some
sensitivity to neutralization by CAP63 serum (IC50 of 212 at 1
yr p.i. compared to an autologous titer of 1,633). The reverse
chimera, 63/88/63-V4, showed some reduction in sensitivity,
dropping from the parental titer of 1,633 to 1,142 at 12 months
p.i., suggesting that in CAP63, NAbs targeting V4 were
present. In the remaining three sera no anti-V4 NAbs were
observed.
V5 chimeras indicated that anti-V5 NAbs were undetectable
in sera from participants CAP45, CAP63, and CAP88. CAP84
serum contained low levels of NAbs directed at the V5 region,
with insertion of the V5 region of CAP84 into the resistant
CAP45 backbone allowing transfer of some sensitivity (IC50 of
120 compared to the autologous titer of 2,447 against CAP84)
and a reciprocal drop in titer when the V5 region was swapped
out (IC50 dropping from 2,447 to 1,551). In general, the role of
antibodies targeting the V4 and V5 regions in autologous neu-
tralization appeared to be minor.
FIG. 3. Amino acid alignment of gp120 from the six parental envelope clones used to construct chimeric viruses. Regions exchanged between
viruses are annotated, and within the C3 region, the 2-helix and -14 and -15 strands are shown. PNGS are highlighted in gray, and amino acids
involved in CD4 binding (40) are indicated by asterisks.
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The C3 region in subtype C is involved in the formation of
NAb epitopes. The 2-helix of the C3 region, which showed
high entropy in the results shown in Fig. 2, has been implicated
in neutralization resistance in subtype C viruses (34). We
therefore also tested four viruses chimeric for the C3 region
against parental sera. As with the other chimeras, we consid-
ered that autologous neutralization may be mediated by anti-
bodies directed at the C3 region if there is acquisition of partial
or complete sensitivity in heterologous viruses in which the
autologous C3 has been introduced.
Neutralization assays using sera from CAP45, CAP84, and
CAP63 against constructs carrying the autologous C3 regions
showed no sensitivity to neutralization, indicating that C3
alone was not a target of NAbs in these three sera (Fig. 4B,
dotted blue lines). However, interestingly, in CAP45 and
CAP84, replacement of the autologous C3 with an unrelated
C3 resulted in a dramatic drop in the titer in both chimeras.
Taken together, these data suggest that C3 in CAP45 and
CAP84 may be involved in the formation of neutralization
epitope(s), as has been proposed by other investigators (34),
though it is not a direct target of NAbs. Replacement of the
CAP63 C3 with CAP88 C3 did not result in a reduction in titer
compared to the parent virus. CAP88 was unique in that 63/
88/63-C3 acquired considerable sensitivity to CAP88 serum,
with a concomitant reduction in the titer of the reverse chi-
mera, 88/63/88-C3, suggesting that in CAP88, C3 may itself be
a direct target of circulating NAbs in this individual.
The C3-V4 region is a major target of autologous neutral-
ization in subtype C infection. In addition to the C3 chimeras,
we constructed viruses chimeric for the C3 through V4 regions,
which have been proposed to be in close proximity and to
interact with one another (9). Significantly, in all four individ-
uals, the introduction of the autologous C3-V4 into a heterol-
ogous parent virus resulted in an increase in sensitivity to
neutralization, with two of the chimeras (63/88/63-C3-V4 and
88/63/88-C3-V4) reaching titers observed in autologous neu-
tralization of the parent virus (Fig. 4B). In all sera tested, the
chimera in which the autologous C3-V4 was swapped out also
had a partial (CAP45, CAP63, and CAP88) or complete
(CAP84) reduction in the sensitivity to parental sera, further
confirming the role of the C3-V4 region as a target of autolo-
gous neutralization in these individuals.
FIG. 4. Neutralization data for chimeric and parental viruses. ID50 titers are shown on the y axis and the number of weeks p.i. are on the x axis.
Solid lines indicate parent viruses; dotted lines indicate chimeras, with the color matching the backbone of the parental viruses. Each graph
represents neutralization data using serum from a single individual, indicated above each column. Shaded boxes indicate transfer of sensitivity in
chimeras. (A) Neutralization data for viruses chimeric for the V1V2, V4, and V5 regions. (B) Neutralization data for viruses chimeric for the C3
and C3-V4 regions.
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Chimeric viruses do not display a generally neutralization-
sensitive phenotype. In order to assess whether the acquisition
of neutralization sensitivity was due to these chimeras’ acquir-
ing a more generally neutralization-sensitive phenotype, per-
haps through more open conformations, we tested them
against heterologous CAPRISA sera obtained 12 months p.i.
We have previously reported that sera from these six individ-
uals, while potently neutralizing the autologous enrollment
virus, showed no cross-reactivity at this time point (12). No
neutralization of chimeras by sera other than the parental sera
was observed, suggesting that acquisition of neutralization sen-
sitivity was specific to the region transferred (Fig. 5). Further-
more, we showed above that all six individuals developed high-
titer anti-V3 binding antibodies. These antibodies, although
unable to neutralize parental viruses, were able to potently
block viral entry of an HIV-2 scaffold into which either subtype
B or C consensus V3 regions have been introduced (K. Davis
et al., unpublished data). The lack of cross-neutralization, de-
spite high titers of anti-V3 antibodies, indicated that the V3
region of these chimeras was not exposed.
DISCUSSION
This study aimed to determine the specificities of NAbs
which mediate potent but type-specific autologous neutraliza-
tion in early HIV-1 subtype C infection. Although high levels
of cross-reactive binding anti-V3 antibodies were detected,
these did not mediate neutralization of primary viruses. NAbs
targeting the V1V2, V4, and V5 regions contributed to autol-
ogous neutralization in some individuals to various degrees,
with V1V2 playing a more significant role than V4 or V5. In
contrast, antibodies directed against the C3-V4 region were
involved in autologous neutralization in all sera tested, sug-
gesting that epitopes in this region are major targets of the
early autologous neutralizing response in subtype C infection.
The V3 region is known to be highly immunogenic, with
most individuals developing antibodies soon after infection
(27). Anti-V3 antibodies developed in these six individuals
within 3 to 12 (median, 5 weeks) weeks, which in five of six
subjects corresponded to the earliest time point tested. This is
considerably earlier than the autologous neutralizing response
in these individuals, which became detectable within a median
of 19 weeks (range, 12 to 37 weeks) (12). These anti-V3 bind-
ing antibodies were characterized by substantial cross-reactiv-
ity, which is not surprising, given that the V3 region in subtype
C viruses is remarkably well conserved (8). Indeed, within the
CAPRISA cohort, two viruses had identical V3 loops (CAP8
and CAP244) but no neutralization cross-reactivity (12). It is
possible that, in a similar manner as has been suggested for
CD4-induced antibodies (4), anti-V3 antibodies play a role in
constraining the virus to shield the V3 loop, thereby limiting
the accessibility of the V3 region. However, the high degree of
conservation in the subtype C V3 suggests that anti-V3 anti-
bodies in subtype C infection are not of great biological rele-
vance in driving viral escape from the neutralization response,
a suggestion which is borne out in this study where we detected
no role for anti-V3 antibodies in autologous neutralization
using peptide adsorption studies.
The role of V1V2 in shielding neutralization determinants is
well recognized (3, 18–20, 30, 35, 39). However, we along with
others have proposed that the V1V2 may also serve as the
FIG. 5. Chimeras do not acquire a generally neutralization-sensitive phenotype. Summary of neutralization data for all chimeras and parental
viruses tested against heterologous sera. Data are shown as neutralization titer (ID50) and are color coded.
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neutralization target in some cases (12, 33). These data suggest
that in some individuals a proportion of autologous neutral-
ization is indeed directed at conformational epitopes con-
tained within the V1V2 region. The role of V4 and V5 was less
significant. Although we did observe some activity directed
against V4 alone (CAP63) and V5 (CAP84), in both these
cases the contribution of antibodies targeting these regions as
a proportion of total autologous neutralization was minor.
Although it was evident that all sera contained some activity
against variable loops, this activity did not account for the total
neutralizing capacity of these sera against the autologous en-
rollment virus. This prompted us to look at other regions
potentially targeted by the early autologous neutralizing re-
sponse.
The C3 region of the HIV-1 subtype C envelope and, in
particular, unique mutational patterns in the 2-helix have
been implicated in neutralization resistance (34). However,
exchange of the 2-helix between resistant donor Env and
sensitive recipient Env did not result in transfer of neutraliza-
tion phenotypes (34), an observation that is generally consis-
tent with our data, where in three of four individuals (Fig. 4B)
viruses containing heterologous C3 regions (including the 2-
helix) did not acquire sensitivity to the matching heterologous
serum. However, of these three sera, it was noticeable that two
of the three reverse chimeras, where the C3 region was re-
moved and replaced with an unrelated C3 region, were much
less sensitive to neutralization than the parental viruses, sug-
gesting that removal of the C3 altered NAb epitopes. This was
not the case in the study by Rong et al. (34), where the re-
placement of the 2-helix did not result in substantial loss of
sensitivity to neutralization. Given the strong interaction be-
tween the -14 strand of C3 and the V4 region (9), it is possible
that replacement of the 2-helix in conjunction with the -14
strand in the C3 chimeras as described in this study had a
deleterious effect on the conformation of the V4 region,
whereas in the 2-helix chimeras described by Rong and co-
workers, the interaction of V4 with the autologous -14 strand
was intact, which afforded some stability to the conformation
of the V4 region. Furthermore, the parent viruses of chimeras
were transmission pairs, with less variation across the entire
envelope.
In general, the 2-helices of subtype B viruses are more
hydrophobic than the subtype C 2-helices, which have more
defined polar and nonpolar faces (9). This increased am-
phipathicity, which is more characteristic of a surface helix, in
subtype C may indicate that the 2-helix is more exposed. The
high levels of switching between oppositely charged residues, a
feature of the subtype C 2-helix and not of subtype B, where
variable positions maintain similar charges, may therefore be a
mechanism of immune escape (9). It has therefore been pro-
posed that NAbs directly target the 2-helix in subtype C
viruses. However, in this study, we observed only one of four
individuals (CAP88) where transfer of the C3 region impli-
cated antibodies targeting this region, although it is not clear
whether these antibodies were specifically directed against the
2-helix or against other regions in C3. It is noteworthy that
the 2-helix of CAP88 contained two hydrophobic residues
which replaced residues that are normally hydrophilic (5I and
6A), and the polar and nonpolar faces have been perturbed
(Fig. 6). It is therefore possible that the anti-C3 activity ob-
served in CAP88 is the result of an unusual conformation of
the 2-helix, possibly altering the exposure of the 2-helix. As
noted above, the C3 region also contains the highly variable
-14 strand, as well as the conserved -15 strand and 3-helix
which contain elements of the CD4 binding site, so it is also
possible the C3-directed activity in CAP88 is mediated by anti-
CD4 binding site (CD4bs) antibodies or others of unknown
specificities. Anti-CD4bs antibodies mediating autologous
neutralization would be interesting to investigate since they are
clearly type specific. Type-specific anti-CD4bs antibodies may
not be entirely surprising as even the monoclonal CD4bs NAb
immunoglobulin G1b12, which is characterized as broadly neu-
tralizing, neutralizes only approximately half of primary iso-
lates (1). Furthermore, there is evidence that the functional
CD4 binding region is smaller than the structural epitope of
immunoglobulin G1b12 (14), perhaps allowing some flexibility
in secondary binding sites to other nonconserved residues (28).
In contrast to C3 or V4 in isolation, both of which seem to
be only sporadically involved in autologous neutralization, chi-
meras containing the C3 region through to V4, when trans-
ferred as a single unit, showed much more dramatic shifts in
their neutralization phenotypes. In all four cases, insertion of
C3-V4 into an insensitive backbone resulted in increased sen-
sitivity, reaching levels at or close to those seen in the autolo-
gous (parental) virus, with a corresponding decrease in sensi-
tivity observed in reverse chimeras. Molecular dynamics
FIG. 6. Helical wheel plot of the 2-helices of viruses from CAP45, CAP84, CAP63, and CAP88. Hydrophilic amino acid residues are shown
in clear circles, and hydrophobic residues are shown in gray circles.
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simulations have indicated that the N-terminal half of the
2-helix of C3 interacts strongly with the C-terminal portion of
V4 (9). Furthermore, it has been proposed that the 2-helix,
though not a direct target of the neutralizing response, may
contribute to the quaternary structure of the trimer and so
affect neutralization epitopes, possibly via the strong interac-
tions this region has with the V4 loop or the with -10, -11,
-14, and -24 strands (34). Our study suggests that the 2-
helix and the V4 loop of subtype C viruses may coevolve during
antibody escape, with the V4 region undergoing mutations and
the 2-helix undergoing concomitant compensatory mutations
which therefore track with neutralization resistance. The con-
formation of V4 may therefore be dependent on the proper
context provided by the 2-helix of the C3 region. The transfer
of sensitivity observed in this study suggests the possibility that
NAbs in all four sera may target the V4 loop but that the
conformation of the epitopes in the V4 region is informed by
the underlying C3 region. This model is further supported by
the C3 chimera data, where in three individuals, and regardless
of the presence of the autologous V4 region, the removal of
the C3 region destroyed the epitope recognized by circulating
NAbs.
The use of chimeras in the study has proven helpful in the
identification of regions which are likely targeted by autolo-
gous NAbs early in infection. However, a caveat to these data
is that variations in the length and glycosylation of the heter-
ologous insert may impact neutralization sensitivity by expo-
sure of epitopes. Furthermore, the exchange of fairly large
portions of the envelope may result in conformational changes
which are hard to predict. Even in cases such as the transfer of
V1V2 between CAP45 and CAP84 (in chimeras 84/45/84-
V1V2 and 45/84/45-V1V2) where the exchanged region was of
equal length and with the same number of predicted glycosy-
lation sites (Table 1), the effect of residues with various charges
and properties on the overall conformation may change. We
have shown that in all cases, the chimeras used in this study did
not acquire a universally sensitive phenotype, with acquisition
of neutralization sensitivity related only to sera from one or
another parent virus. These data suggest that where we ob-
served acquisition of neutralization sensitivity in chimeras, this
is likely through transfer of epitopes rather than through gross
conformational changes.
In general, results obtained using reverse chimeras mirrored
the constructs where regions of interest were swapped in, al-
though this was not always the case. For example, the chimera
88/63/88-C3-V4 acquired complete sensitivity to neutralization
by CAP63 sera, but in the reverse chimera, 63/88/63-C3-V4,
the titers did not drop substantially (Fig. 4B). This may be
explained by the presence of other antibody specificities in
CAP63 sera which are magnified in the absence of the autol-
ogous C3-V4 epitope. The contribution of each specificity to
the total neutralizing capacity, as measured by the chimeras, is,
however, unlikely to be additive. Chimeras may have subtle
conformational changes which could alter the efficiency of en-
try compared to parental viruses, leading to over- or underes-
timates of the proportions of other antibody specificities. Al-
though neutralization assays using gp120-gp41 chimeras
suggest that autologous neutralization is not mediated by anti-
gp41 antibodies (data not shown), there are almost certainly
other antibody specificities present in these sera, which could
perhaps only be measured using chimeras where larger subre-
gions are transferred together. Indeed, in serum from CAP45,
the role of both anti-V1V2 and anti-C3-V4 antibodies seems
relatively minor, suggesting that as yet unidentified specificities
likely contribute to autologous neutralization in this serum.
Our results indicate that autologous neutralization may be
targeted to multiple regions of the gp120. However, a common
and striking feature of autologous neutralization in these sera
is a high level of antibodies targeting the C3-V4 region, which
includes the 2-helix and some determinants of the CD4bs.
These data support available bioinformatics data implicating
the 2-helix in neutralization resistance in subtype C and fur-
ther supporting suggestions that the C3 region in subtype C has
distinct structural features from that of subtype B. It is perhaps
surprising, given the type-specific nature of the autologous
response, that the same region was targeted in all four indi-
viduals. Clearly, the antibody specificities are distinct, and fu-
ture work will aim to precisely define the epitopes in this
region. Elucidation of the specificities of early autologous
NAbs in a globally prevalent subtype will enable studies to
understand the mechanism whereby neutralization breadth de-
velops and will provide information regarding accessible
epitopes on the transmitted early virus which may inform vac-
cine design.
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